Skip to main content
TipRanks
Go Ultimate75% OFF

Imunon (CBO0) Q3 2026 Earnings Report

2 Followers

DE:CBO0 Q3 2026 EPS Results

Actual EPS
-EUR 0.58
Consensus EPS
-EUR 0.50
Beat/Miss
Missed by -EUR 0.08
One Year Ago EPS
-EUR 1.06

DE:CBO0 Q3 2026 Revenue Results

Actual Revenue
EUR 0
Expected Revenue
EUR 0
Beat/Miss
Met expectations
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q3 2026
Date
11/12/2026
Time
Before Open
Conference Call
Thursday, November 12, 2026
DE:CBO0 Upcoming Earnings

Imunon's next earnings date is estimated for April 1, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:CBO0 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 12, 2026|% Change Since:-22.33%|
Earnings Call Sentiment|Positive

The call was predominantly positive regarding IMNN-001, with management highlighting strong OVATION-3 enrollment productivity, favorable safety findings, encouraging preliminary MRD data, supportive overall survival results from OVATION-2, independent validation, and portfolio and balance-sheet actions focused on the Phase III program. However, the company continues to face substantial financing risk, disclosed substantial doubt about its ability to continue as a going concern, and requires additional capital to complete OVATION-3. The positive clinical and operational updates significantly outweighed the stated financial and execution challenges.

Company Guidance

Imunon is targeting 50% enrollment in the first quarter of 2028 and completion of enrollment in the first quarter of 2029 for OVATION-3, with all planned sites activated by the end of 2027; the first preplanned interim analysis, aimed at the full intent-to-treat population versus the HRD-positive subgroup, will occur at 60% of the targeted overall survival events and is currently estimated for the first quarter of 2030, assuming continued site activation and enrollment rates consistent with recent performance and subject to the usual variability of oncology trial execution. Across active sites, average enrollment has been approximately 0.4 patients per site per month versus a planning assumption of approximately 0.3, and the company said completing the trial and activating 50 sites requires additional capital.

  • OVATION-3 Enrollment Tracking to PlanEnrollment in the pivotal Phase III OVATION-3 study is tracking consistently with the company's plan. Average enrollment across active sites has been approximately 0.4 patients per site per month, above the planning assumption of approximately 0.3 patients per site per month.
  • Progress on Site Activation and Enrollment MilestonesAt the end of the quarter, 18 OVATION-3 sites had been selected, with 9 active and 9 in start-up. The company is targeting 50% enrollment in the first quarter of 2028, completion of enrollment in the first quarter of 2029, and activation of all planned sites by the end of 2027.
  • Defined Path to Interim AnalysesThe first preplanned interim analysis is aimed at the full intent-to-treat population versus the HRD-positive subgroup and is expected to occur at 60% of targeted overall survival events, currently estimated for the first quarter of 2030. The trial includes two preplanned event-driven interim analyses that could support an earlier submission for full approval if prespecified statistical thresholds are met.
  • Efficient Trial OperationsOVATION-3 site activation has advanced from protocol submission to site activation in approximately 6 months and from protocol approval to first patient randomized in approximately 2 months, roughly one-third of external industry benchmarks.
  • Favorable OVATION-3 Safety ProfileAcross OVATION-2, the MRD study, and OVATION-3, the company reported no cytokine release syndrome, no systemic toxicities, and no serious immune-related adverse events. Safety remains comparable across both treatment arms, and the independent data monitoring committee identified no new safety concerns in OVATION-3.
  • Positive MRD Study Preliminary FindingsAmong patients who reached the primary assessment at second-look laparoscopy, IMNN-001 was associated with a lower MRD positivity rate than the control arm, 44.4% versus 66.7%; higher circulating tumor DNA clearance, 87.5% versus 62.5%; and a higher proportion achieving no evidence of disease following frontline therapy, 100% versus 56%.
  • Longer Recurrence-Free Survival in MRD StudyIn the 26-patient intent-to-treat MRD cohort, median recurrence-free survival was approximately twice as long in the IMNN-001 arm, at 26.1 months versus 11.4 months. The company emphasized that the study was hypothesis generating rather than confirmatory, with a log-rank p-value of 0.17.
  • Independent Confirmation of MRD SafetyThe independent Data and Safety Monitoring Committee reviewed all MRD safety data and recommended that the study continue without modification, identifying no new safety signals and confirming comparable safety across both treatment arms. The study demonstrated safety and tolerability of IMNN-001 in combination with bevacizumab and in the maintenance setting.
  • Evidence of Tumor Microenvironment RemodelingTranslational analyses showed robust IL-12 expression within macrophages, activation of downstream cytokines including interferon gamma, macrophage and T-cell activation, macrophage uptake of IMNN-001, and expansion of T-cell receptor clones. The company described these findings as consistent with remodeling of the tumor microenvironment from an immunologically cold state to an immunologically active or hot state.
  • OVATION-2 Overall Survival SignalOVATION-2 demonstrated a 14.7-month increase in median survival, 45.1 months versus 30.4 months, and a 24.2-month increase among patients who received PARP inhibitor maintenance, 65.6 months versus 41.4 months. The difference in median survival increased from 11.4 months at the July 2024 readout to 14.7 months at the final analysis in December 2025.
  • External Validation and Scientific VisibilityThe company cited validation from the National Cancer Institute, independent data monitoring committees, and clinical investigators who presented at the September R&D Day. IMNN-001 was also presented at ASCO, AACR's inaugural Conference on Drug Discovery and Development, and the Society for Immunotherapy of Cancer meeting, with the final OVATION-2 overall survival analysis planned for presentation at a major medical meeting in 2027.
  • NCI CRADA Expands IMNN-001 DevelopmentImunon entered into a Cooperative Research and Development Agreement with the National Cancer Institute's Cancer Therapy Evaluation Program. Under the agreement, NCI investigators will evaluate IMNN-001 in additional solid tumor indications and combination regimens, with NCI assuming regulatory sponsorship and operational responsibility for the studies.
  • Capital-Efficient NCI CollaborationThe company stated that the CRADA provides a highly capital-efficient opportunity to generate clinical trial evidence without diverting resources from OVATION-3. Imunon will retain ownership of its background intellectual property and new intellectual property solely generated by Imunon under the collaboration, including the right to use collaboration-generated data for IMNN-001 research and development.
  • ThermoDox Transaction Creates Potential Future ValueImunon agreed to sell its ThermoDox rights to VoxelDox Therapeutics, which intends to advance the asset in glioblastoma. Upon closing, Imunon would receive an approximately 4.76% equity interest in VoxelDox, potential aggregate development and sales-based milestone payments of up to $16.5 million, and tiered royalties ranging from 3.5% to 6% on net sales of ThermoDox-related products if approved.
  • Debt Reduction Without Common Stock or WarrantsIn late September, Imunon exchanged $1.2 million of outstanding debt plus accrued interest for nonconvertible preferred stock, reducing the balance of that note by approximately 43% without issuing common stock or warrants.
  • Expense Discipline and Stock-Based CompensationLeadership team members, a broader employee base, and consultants voluntarily elected to take a meaningful portion of their base salary in stock rather than cash. General and administrative expenses remained essentially flat year-over-year during the first three quarters of 2026 while the company was running a Phase II trial and a Phase III trial.
  • Renewed Industry Interest in IL-12Management cited renewed interest in IL-12 across clinical and preclinical programs and said the activity validates the potential of IL-12 and Imunon's approach. The company stated that the other programs discussed at the Society for Immunotherapy of Cancer meeting were early-stage and that IMNN-001 was years ahead in development, with established safety and clinical activity in randomized controlled trials.
  • Stable Third-Quarter Operating ExpensesThird-quarter research and development expenses were $1.8 million, compared with $1.9 million in the same period last year. General and administrative expenses were $1.7 million, compared with $1.6 million a year ago.

DE:CBO0 Earnings History

DE:CBO0 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Apr 01, 20272026 (Q4)-0.45--0.77――
Nov 12, 20262026 (Q3)-0.50-0.58-1.0644.83% (+0.47)
Aug 11, 20262026 (Q2)-0.79-0.49-1.771.12% (+1.21)
May 12, 20262026 (Q1)―--3.33―
Mar 31, 20262025 (Q4)-1.11-0.77-3.3377.00% (+2.56)
Nov 13, 20252025 (Q3)-1.09-1.06-4.0473.84% (+2.99)
Aug 05, 20252025 (Q2)-3.77-1.70-6.0671.89% (+4.36)
May 12, 20252025 (Q1)-4.16-3.33-6.1846.16% (+2.85)
Feb 27, 20252024 (Q4)-4.26-2.97-5.9550.00% (+2.97)
Nov 07, 20242024 (Q3)-4.61-4.04-4.48.10% (+0.36)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed